CPT® Code 81236

EZH2 (enhancer of zeste 2 polycomb repressive complex 2 subunit) (eg, myelodysplastic syndrome, myeloproliferative neoplasms) gene analysis, full gene sequence

The CPT® Code 81236 pertains to the molecular genetic testing of the EZH2 gene, which stands for enhancer of zeste 2 polycomb repressive complex 2 subunit. This testing involves a comprehensive analysis of the full gene sequence associated with specific hematological disorders, namely myelodysplastic syndrome (MDS) and myeloproliferative neoplasms (MPN). The EZH2 gene is situated on the long (q) arm of chromosome 7 at the position designated as 7q36.1. It encodes for an enzyme known as histone methyltransferase, which plays a crucial role in modifying histone proteins through the addition of methyl groups. This methylation process can enhance the function of these proteins or lead to atypical functions that disrupt the normal regulatory mechanisms of cell division and proliferation. Consequently, this disruption can result in uncontrolled cell division, while simultaneously suppressing the self-renewal and differentiation of cells. MDS and MPN are conditions that arise when the bone marrow is unable to produce sufficient quantities of healthy blood cells, including red blood cells, white blood cells, and platelets. These disorders are characterized by the presence of an excessive number of blast cells and the production of underdeveloped or immature blood cells that exhibit abnormal shapes, sizes, or characteristics. Patients suffering from these conditions may experience a range of symptoms, including fatigue, weight loss, pallor, tachycardia, respiratory difficulties, fever, increased susceptibility to infections, bruising, abnormal bleeding, and the appearance of petechiae. The analysis performed under code 81236 involves a detailed examination of the EZH2 gene's full sequence, allowing for the comparison of gene segments to identify similarities or differences, as well as to establish relationships. This genetic testing can uncover specific genetic markers by detecting point mutations or single nucleotide polymorphisms, which are critical for understanding the underlying genetic factors associated with these hematological disorders.